Creek Group

Discovering new medicines for malaria using proteomics and metabolomics

Malaria is a major global health problem, and there is a pressing need to discover new antimalarial medicines. Current antimalarial drugs have been severely undermined by widespread emergence of drug-resistant strains, highlighting the urgent need for novel therapies.

By using advanced metabolomics and proteomics technologies, we are able to improve our understanding of metabolic networks and drug-target interactions.

Our research aims to reveal new aspects of malaria parasite biology, identify drug targets for promising antimalarial compounds, and improve the diagnostic and treatment options for malaria in this challenging era of multi-drug resistance.

We are part of the Drug Delivery Disposition and Dynamics theme of the Monash Institute of Pharmaceutical Sciences. Our research falls under the Global Health Therapeutic Program Area.

Group leader

Learn more about us